Comparison
Semaglutid vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
910463-68-2
no data
Molecular weight
4113.6 g/mol
888 g/mol
Half-life
165 h
no data
Sequence
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerAc-LKKTETQMechanism of action
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human RCT
Animal model
Studies
4
3
of which in humans
3
0
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
5
2